Eli Lilly (NYSE: LLY) is having a notably underwhelming year by its own high standards, posting gains that fall short of what investors have come to expect.
As of Monday’s close, LLY shares were up around 8% for the year, a decent return on its own but trailing the S&P 500, which is up 13% over the same period.
The last time Eli Lilly failed to deliver double-digit annual returns was 2016, when the stock actually declined by nearly 13%.
That historical benchmark makes 2026 a potential inflection point for a company that has otherwise been one of the most reliable growth stories in the healthcare sector.
Since 2017, Eli Lilly has generated annual returns of at least 10% every single year, making its current performance stand out as a meaningful departure from recent form.
Much of the stock’s recent sluggishness appears tied to valuation concerns, with LLY currently trading at close to 40 times its trailing earnings, a figure that gives some investors pause.
Over the past five years, the company’s valuation has soared by more than 400%, reflecting enormous investor enthusiasm for its GLP-1 drug portfolio and the record revenue and profit that has followed.
Significant demand for its GLP-1 drugs has driven exceptional financial results, and the company’s growth rate has been accelerating, which historically justified paying a premium for the stock.
However, competition in the GLP-1 market is growing, with many healthcare companies developing their own drugs to capture a share of what has become one of the most lucrative segments in modern medicine.
Paying a high premium may be difficult to justify given the long-term uncertainty in the GLP-1 market, particularly as rival treatments advance through development pipelines.
Eli Lilly still has significant growth opportunities ahead, not only in GLP-1 drugs but also across other areas of healthcare where its research and commercial reach continue to expand.
Despite those long-term prospects, there is limited margin of safety at current valuations should growth slow due to rising competition or unexpected regulatory developments in the healthcare sector.
Investors buying LLY at today’s elevated prices should be prepared for the possibility that lower, more modest returns become the norm going forward, even if the underlying business continues to perform well.
The company remains a dominant force in its space, but the gap between its stock performance and the broader market in 2026 signals that even the strongest growth names are not immune to valuation gravity.
